FR21C1010I1 - - Google Patents

Info

Publication number
FR21C1010I1
FR21C1010I1 FR21C1010C FR21C1010I1 FR 21C1010 I1 FR21C1010 I1 FR 21C1010I1 FR 21C1010 C FR21C1010 C FR 21C1010C FR 21C1010 I1 FR21C1010 I1 FR 21C1010I1
Authority
FR
France
Prior art keywords
sub
sup
kinase
fak
cdk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR21C1010I1 publication Critical patent/FR21C1010I1/fr
Application granted granted Critical
Publication of FR21C1010I2 publication Critical patent/FR21C1010I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
FR21C1010C 2000-03-01 2021-02-23 2,4,di-(hetero-) arylamino (-oxy)-5 pyrimidines substitutees utilisees comme agents antineoplasiques Active FR21C1010I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0004887.6A GB0004887D0 (en) 2000-03-01 2000-03-01 Chemical compounds
PCT/GB2001/000829 WO2001064656A1 (en) 2000-03-01 2001-02-26 2,4,di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents

Publications (2)

Publication Number Publication Date
FR21C1010I1 true FR21C1010I1 (de) 2021-05-07
FR21C1010I2 FR21C1010I2 (fr) 2022-02-11

Family

ID=9886703

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1010C Active FR21C1010I2 (fr) 2000-03-01 2021-02-23 2,4,di-(hetero-) arylamino (-oxy)-5 pyrimidines substitutees utilisees comme agents antineoplasiques

Country Status (25)

Country Link
US (2) US6838464B2 (de)
EP (1) EP1278735B1 (de)
JP (2) JP2003525279A (de)
KR (2) KR100855258B1 (de)
CN (1) CN1220684C (de)
AT (1) ATE472537T1 (de)
AU (2) AU3397901A (de)
BE (1) BE2021C507I2 (de)
BR (1) BR0108879A (de)
CA (1) CA2398887C (de)
CY (1) CY1111093T1 (de)
DE (1) DE60142469D1 (de)
DK (1) DK1278735T3 (de)
ES (1) ES2346288T3 (de)
FR (1) FR21C1010I2 (de)
GB (1) GB0004887D0 (de)
HK (1) HK1053111B (de)
IL (2) IL150920A0 (de)
LU (1) LUC00197I2 (de)
MX (1) MXPA02007581A (de)
NO (2) NO325443B1 (de)
NZ (1) NZ520502A (de)
PT (1) PT1278735E (de)
WO (1) WO2001064656A1 (de)
ZA (1) ZA200206192B (de)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1107958B1 (de) 1998-08-29 2006-08-16 AstraZeneca AB Pyrimidine verbindungen
JP2002523497A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
HUP0302173A2 (hu) * 2000-09-15 2003-09-29 Vertex Pharmaceuticals Incorporated Protein kináz inhibitorokként alkalmazható pirazolvegyületek
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ES2265452T3 (es) 2000-12-21 2007-02-16 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de la proteina quinasa.
NZ526542A (en) 2000-12-21 2005-01-28 Glaxo Group Ltd Pyrimidineamines as angiogenesis modulators
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) * 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
US20030139435A1 (en) 2001-06-26 2003-07-24 Gulzar Ahmed N-heterocyclic inhibitors of TNF-alpha expression
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) * 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
WO2003026664A1 (en) * 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
WO2003040141A1 (en) * 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
JP4460292B2 (ja) 2001-10-17 2010-05-12 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
US7361668B2 (en) * 2001-10-17 2008-04-22 Ucb, S.A. Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
AU2002367172A1 (en) * 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
RU2004126671A (ru) * 2002-02-06 2005-04-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероарилсоединения, полезные в качестве ингибиторов gsk-3
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2003076434A1 (en) 2002-03-09 2003-09-18 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US20040009981A1 (en) * 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003231231A1 (en) * 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
EP2316459B1 (de) * 2002-07-29 2013-11-06 Rigel Pharmaceuticals, Inc. 2,4-Pyrimidindiaminen zur Behandlung oder Vorbeugung von Autoimmunerkrankungen
CN103169708B (zh) * 2002-07-29 2018-02-02 里格尔药品股份有限公司 用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
WO2004016581A1 (en) * 2002-08-09 2004-02-26 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
US7109337B2 (en) * 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EP1625121B1 (de) * 2002-12-20 2010-02-24 Pfizer Products Inc. Pyrimidin-derivate zur behandlung von anormalem zellwachstum
DE602004021558D1 (de) * 2003-01-17 2009-07-30 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
DE602004022633D1 (de) 2003-01-30 2009-10-01 Boehringer Ingelheim Pharma 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
WO2004072029A2 (en) * 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
US7157455B2 (en) 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
DE602004021472D1 (en) * 2003-02-20 2009-07-23 Smithkline Beecham Corp Pyrimiidinverbindungen
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
RS53109B (en) 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. 2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
DK1660458T3 (da) * 2003-08-15 2012-05-07 Irm Llc 2, 4-pyrimidindiaminer egnede i behandling af neoplastiske sygdomme, in-flammatoriske lidelser og lidelser i immunsystemet.
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
EP1663992A1 (de) * 2003-09-18 2006-06-07 Novartis AG 2,4-di (phenylamino) pyrimidine, die sich zur behandlung von proliferativen erkrankungen eignen
EP1678169B1 (de) 2003-10-17 2009-07-22 Astrazeneca AB 4-(pyrazol-3-ylamino)pyrimidinderivate zur verwendung bei der behandlung von krebs
GB0324551D0 (en) * 2003-10-21 2003-11-26 Karobio Ab Novel compounds
CA2548172A1 (en) * 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
FR2866879A1 (fr) * 2004-02-27 2005-09-02 Oreal Para-phenylenediamine secondaire n-alkylaminee, composition de teinture des fibres keratiniques contenant une telle para-phenylenediamine, procedes mettant en oeuvre cette composition et utilisations
US7338536B2 (en) 2004-02-27 2008-03-04 L'oreal S. A. N-alkylamino secondary para-phenylenediamine, composition for dyeing keratin fibers comprising such a para-phenylenediamine, processes using this composition and uses thereof
WO2005096784A2 (en) * 2004-04-08 2005-10-20 Targegen, Inc. Benzotriazine inhibitors of kinases
JP2007537238A (ja) * 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療のためのピリミジン誘導体
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CA2566477A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06013164A (es) 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
AU2005276974B2 (en) 2004-08-25 2012-08-02 Targegen, Inc. Heterocyclic compounds and methods of use
CA2587427A1 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
ATE540035T1 (de) 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
NZ555474A (en) * 2004-12-17 2010-10-29 Astrazeneca Ab 4-(4-(imidazol-4-yl) pyrimidin-2-ylamino) benzamides as CDK inhibitors
ES2337496T3 (es) 2005-01-19 2010-04-26 Rigel Pharmaceuticals, Inc. Profarmacos de compuestos de 2,4-pirimidindiamina y sus usos.
PT1853588E (pt) 2005-02-16 2008-08-25 Astrazeneca Ab Compostos químicos
US20080287437A1 (en) 2005-05-16 2008-11-20 Astrazeneca Ab Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
JP2008543775A (ja) * 2005-06-08 2008-12-04 ターゲジェン インコーポレーティッド 眼の障害を治療するための方法および組成物
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
NZ563454A (en) 2005-06-08 2011-03-31 Rigel Pharmaceuticals Inc 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
CN101213187B (zh) 2005-06-28 2012-06-06 塞诺菲-安万特股份有限公司 作为rho-激酶抑制剂的异喹啉衍生物
KR101373535B1 (ko) 2005-07-26 2014-03-12 사노피 Ｒｈｏ-키나제 억제제로서의 피페리디닐-치환된 이소퀴놀론유도체
WO2007012422A1 (en) 2005-07-26 2007-02-01 Sanofi-Aventis Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
EP2301928A1 (de) * 2005-07-30 2011-03-30 AstraZeneca AB Imidazolylpyrimidinverbindungen zur Verwendung bei der Behandlung von proliferativen Erkrankungen
ATE542814T1 (de) * 2005-08-18 2012-02-15 Vertex Pharma Pyrazinkinaseinhibitoren
CA2623374A1 (en) 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
KR101487027B1 (ko) * 2005-09-30 2015-01-28 미카나 테라퓨틱스, 인크. 치환된 피라졸 화합물
PL1945631T3 (pl) 2005-10-28 2012-12-31 Astrazeneca Ab Pochodne 4-(3-aminopirazolo)pirymidyny do stosowania jako inhibitory kinazy tyrozynowej do leczenia raka
AU2012230091B2 (en) * 2005-11-01 2015-04-23 Impact Biomedicines, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
NZ592990A (en) * 2005-11-01 2013-01-25 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
UA109412C2 (uk) * 2005-11-01 2015-08-25 5-метил-n2-[4-(4-метилпіперазин-1-іл)феніл]-піримідин-2,4-діамін та його застосування в способі одержання сполуки
AR056763A1 (es) * 2005-11-03 2007-10-24 Vertex Pharma Aminopirimidinas sustituidas con tiazol o pirazol,utiles como agentes anticancer y composiciones farmaceuticas que las contienen.
US7705009B2 (en) 2005-11-22 2010-04-27 Hoffman-La Roche Inc. 4-aminopyrimidine-5-thione derivatives
AP2008004488A0 (en) * 2005-12-21 2008-06-30 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CA2642211C (en) 2006-02-17 2012-01-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
ES2633318T3 (es) 2006-10-23 2017-09-20 Cephalon, Inc. Derivados bicíclicos fusionados de 2,4-diaminopirimidina como inhibidores de ALK y c-Met
EP2086965B1 (de) * 2006-11-02 2010-02-10 Vertex Pharmaceuticals, Inc. Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
AU2007333394C1 (en) * 2006-12-08 2011-08-18 Novartis Ag Compounds and compositions as protein kinase inhibitors
MY148427A (en) 2006-12-08 2013-04-30 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2099787B1 (de) * 2006-12-19 2010-07-21 Vertex Pharmaceuticals, Inc. Als inhibitoren von proteinkinasen geeignete aminopyrimidine
JP5405314B2 (ja) 2006-12-27 2014-02-05 サノフイ シクロアルキルアミン置換イソキノロン誘導体
CA2673920C (en) 2006-12-27 2015-03-24 Sanofi-Aventis Cycloalkylamine substituted isoquinoline derivatives
RU2009128690A (ru) 2006-12-27 2011-02-10 Санофи-Авентис (Fr) Новые замещенные производные изохинолина и изохинолинона
JP5318779B2 (ja) 2006-12-27 2013-10-16 サノフイ シクロアルキルアミン置換イソキノリン及びイソキノリノン誘導体
AU2007338408B2 (en) 2006-12-27 2012-07-26 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
MX2009005825A (es) 2006-12-27 2009-06-16 Sanofi Aventis Derivados de isoquinolina e isoquinolinona sustituidos en calidad de inhibidores de rho-quinasa.
TW200902010A (en) 2007-01-26 2009-01-16 Smithkline Beecham Corp Anthranilamide inhibitors of aurora kinase
AU2008226466B2 (en) * 2007-03-09 2013-06-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
MX2009009590A (es) * 2007-03-09 2009-11-10 Vertex Pharma Aminopirimidinas utiles como inhibidores de proteinas cinasas.
WO2008112646A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
JP5569956B2 (ja) * 2007-03-16 2014-08-13 ザ スクリプス リサーチ インスティテュート 接着斑キナーゼのインヒビター
CN101677554A (zh) * 2007-03-20 2010-03-24 史密丝克莱恩比彻姆公司 化合物
JP2010523700A (ja) 2007-04-13 2010-07-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリミジン
UA97834C2 (ru) * 2007-04-18 2012-03-26 Пфайзер Продактс Инк. Производные сульфониламида для лечения анормального роста клеток
CA2685876A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
AU2008247595A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
CA2694381A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
US20100210700A1 (en) 2007-05-08 2010-08-19 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
CN101687852A (zh) * 2007-05-24 2010-03-31 沃泰克斯药物股份有限公司 可用作激酶抑制剂的噻唑类和吡唑类化合物
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
WO2008154026A1 (en) * 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
WO2009010794A1 (en) * 2007-07-19 2009-01-22 Astrazeneca Ab 2,4-diamino-pyrimidine derivatives
WO2009018415A1 (en) * 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
PT2200436E (pt) 2007-09-04 2015-04-29 Scripps Research Inst Pirimidinilaminas substituídas como inibidoras da proteína quinase
JP2011512413A (ja) * 2008-02-19 2011-04-21 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｆａｋの阻害剤としてのアニリノピリジン
SI2300013T1 (en) 2008-05-21 2018-03-30 Adriad Pharmacaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US8524737B2 (en) 2008-06-24 2013-09-03 Sanofi Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives
SI2303846T1 (sl) 2008-06-24 2015-08-31 Sanofi Substituirani izokinolini in izokinolinoni kot inhibitorji RHOP kinaze
PL2313374T3 (pl) 2008-06-24 2014-03-31 Sanofi Sa 6-podstawione izochinoliny i izochinolinony
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP2323622A1 (de) * 2008-09-03 2011-05-25 Vertex Pharmaceuticals Incorporated Co-kristalle und diese enthaltende pharmazeutische formulierungen
WO2010129053A2 (en) 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
EP2464642A4 (de) * 2009-08-12 2013-01-09 Poniard Pharmaceuticals Inc Verfahren zur förderung von apoptose und zur metastasenhemmung
US8466155B2 (en) 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
CN103313697B (zh) 2010-06-29 2016-06-01 维瑞斯特姆股份有限公司 激酶抑制剂的口服制剂
AU2011280031B2 (en) 2010-06-30 2015-09-10 Verastem, Inc. Synthesis and use of Kinase inhibitors
BR112013003388A2 (pt) 2010-08-10 2016-07-12 Celgene Avilomics Res Inc sal de besilato de um inibidor de btk
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
MX2013004894A (es) 2010-11-01 2013-10-17 Celgene Avilomics Res Inc Compuestos heterociclicos y usos de los mismos.
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
EP2637502B1 (de) 2010-11-10 2018-01-10 Celgene CAR LLC Mutanten-selektive egfr-hemmer und verwendungen davon
CA2827171C (en) 2011-02-17 2019-04-09 Cancer Therapeutics Crc Pty Limited Fak inhibitors
CA2827172C (en) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
EP2704572B1 (de) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Verfahren zur hemmung der zellproliferation bei efgr-vermitteltem krebs
EP2770830A4 (de) 2011-10-28 2015-05-27 Celgene Avilomics Res Inc Verfahren zur behandlung einer bruton-tyrosinkinase-erkrankung oder -störung
CA2866852C (en) 2012-03-15 2020-12-29 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US9108927B2 (en) 2012-03-15 2015-08-18 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN103059030B (zh) * 2012-12-28 2015-04-29 北京师范大学 一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
MX2017003928A (es) 2014-09-26 2017-06-28 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas de accion prolongada.
US11254696B2 (en) 2017-12-21 2022-02-22 Shenzhen Targetrx, Inc. Dianilinopyrimidine compound for inhibiting kinase activity
EP3994132A1 (de) * 2019-07-03 2022-05-11 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosinkinase-nicht-rezeptor-1(tnk1)-inhibitoren und deren verwendungen
TW202133858A (zh) 2019-11-28 2021-09-16 日商鹽野義製藥股份有限公司 以組合整合酶阻礙劑及抗ｈｉｖ藥為特徵之ｈｉｖ感染症的預防及治療用醫藥
KR20220109389A (ko) 2019-11-29 2022-08-04 스키피오 라이프 사이언스 리미티드 릴피비린을 포함하는 조성물 및 종양 또는 암 치료를 위한 이의 용도
CN115443269A (zh) 2020-03-31 2022-12-06 施万生物制药研发Ip有限责任公司 经取代的嘧啶和使用方法
CN112390760B (zh) * 2020-10-15 2022-07-29 北京师范大学 靶向fak的化合物及其制备方法和应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946956A (en) 1988-09-21 1990-08-07 Uniroyal Chemical Company, Inc. Arylenediamine substituted pyrimidines
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US4983608A (en) 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (de) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
DK0664291T3 (da) 1992-10-05 2000-10-30 Ube Industries Pyrimidinforbindelse
US5612340A (en) 1993-10-01 1997-03-18 Ciba-Geigy Corporation Pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
PT672042E (pt) 1993-10-01 2006-08-31 Novartis Ag Derivados de pirimidinoamina farmacologicamente activos e processos para a sua preparacao
PL179417B1 (en) 1993-10-01 2000-09-29 Novartis Ag Pharmacologically active derivatives of pyridine and methods of obtaining them
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
ES2201112T3 (es) 1994-08-13 2004-03-16 Yuhan Corporation Nuevos derivados de pirimidina y procedimientos para su preparacion.
EP0813525B9 (de) 1995-03-10 2004-02-04 Berlex Laboratories, Inc. Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
JP2000507558A (ja) 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
AU2381397A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
JP3418624B2 (ja) 1996-06-10 2003-06-23 メルク エンド カンパニー インコーポレーテッド サイトカイン阻害活性を有する置換イミダゾール類
US5780446A (en) 1996-07-09 1998-07-14 Baylor College Of Medicine Formulations of vesicant drugs and methods of use thereof
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
AU5147598A (en) 1996-10-17 1998-05-11 Smithkline Beecham Corporation Methods for reversibly inhibiting myelopoiesis in mammalian tissue
WO1998018096A1 (en) 1996-10-23 1998-04-30 Gtn Technologies, L.L.C. Transportation reservation system
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
AU749750B2 (en) 1997-02-05 2002-07-04 Warner-Lambert Company Pyrido {2,3-d} pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
DE19710435A1 (de) 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
AU734009B2 (en) 1997-05-30 2001-05-31 Merck & Co., Inc. Novel angiogenesis inhibitors
CA2293436C (en) 1997-06-12 2010-10-26 Rhone-Poulenc Rorer Limited Imidazolyl-cyclic acetals as tnf inhibitors
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
EP1019391A1 (de) 1997-10-02 2000-07-19 Merck & Co. Inc. Inhibitoren der prenyl-protein transferase
CA2316296A1 (en) 1997-10-10 1999-04-22 Imperial College Of Science, Technology And Medicine Use of csaidtm compounds for the management of uterine contractions
EP1054004B1 (de) 1997-12-15 2008-07-16 Astellas Pharma Inc. Pyrimidin-5-carboxamid-derivate
WO1999032121A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
BR9908004A (pt) 1998-02-17 2001-12-18 Tularik Inc Composto, composição e método para prevençãoou supressão de uma infecção viral
AU751573C (en) 1998-03-27 2003-10-09 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidine derivatives
JP2002523497A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
EP1107958B1 (de) 1998-08-29 2006-08-16 AstraZeneca AB Pyrimidine verbindungen
ES2253930T3 (es) 1998-09-18 2006-06-01 ABBOTT GMBH & CO. KG 4-aminopirrolopirimidinas como inhibidores de quinasa.
NZ510588A (en) 1998-09-18 2003-08-29 Abbott Gmbh & Co Pyrrolopyrimidines as protein kinase inhibitors
US6531477B1 (en) 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
WO2000025780A1 (en) 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
WO2000026209A1 (en) 1998-11-03 2000-05-11 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
CN1353713A (zh) 1999-02-01 2002-06-12 Cv治疗公司 依赖细胞周期蛋白的激酶2和IκB－α的嘌呤抑制剂
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6627633B2 (en) 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
CA2277689A1 (fr) 1999-07-09 2001-01-09 Krystyna Drya-Lisiecka Construction alveolaire transdynamique
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
WO2001030778A1 (en) 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use
TR200201364T2 (tr) 1999-11-22 2002-10-21 Smithkline Beecham P. L. C. Yeni bileşikler.
IL150420A0 (en) 1999-12-28 2002-12-01 Pharmacopeia Inc Pyrimidine and triazine kinase inhibitors
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2003076434A1 (en) 2002-03-09 2003-09-18 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
LUC00197I1 (de) 2021-02-23
GB0004887D0 (en) 2000-04-19
CN1416423A (zh) 2003-05-07
JP4801335B2 (ja) 2011-10-26
CY1111093T1 (el) 2015-06-11
US20030181474A1 (en) 2003-09-25
AU3397901A (en) 2001-09-12
KR20020075463A (ko) 2002-10-04
ATE472537T1 (de) 2010-07-15
EP1278735A1 (de) 2003-01-29
US7067522B2 (en) 2006-06-27
BE2021C507I2 (de) 2021-02-26
AU2001233979B2 (en) 2004-11-11
NO20024126D0 (no) 2002-08-29
EP1278735B1 (de) 2010-06-30
KR100855258B1 (ko) 2008-08-29
PT1278735E (pt) 2010-08-12
WO2001064656A1 (en) 2001-09-07
ES2346288T3 (es) 2010-10-14
IL150920A0 (en) 2003-02-12
DK1278735T3 (da) 2010-08-30
DE60142469D1 (de) 2010-08-12
JP2005041878A (ja) 2005-02-17
US20050090515A1 (en) 2005-04-28
BR0108879A (pt) 2003-04-29
LUC00197I2 (de) 2021-07-05
NZ520502A (en) 2004-05-28
KR20070106806A (ko) 2007-11-05
US6838464B2 (en) 2005-01-04
ZA200206192B (en) 2003-11-26
FR21C1010I2 (fr) 2022-02-11
JP2003525279A (ja) 2003-08-26
NO325443B1 (no) 2008-05-05
CN1220684C (zh) 2005-09-28
HK1053111A1 (en) 2003-10-10
MXPA02007581A (es) 2002-12-13
HK1053111B (zh) 2011-02-18
CA2398887C (en) 2008-12-16
NO2021008I1 (no) 2021-02-22
CA2398887A1 (en) 2001-09-07
IL150920A (en) 2009-08-03
NO20024126L (no) 2002-08-29

Similar Documents

Publication Publication Date Title
LUC00197I2 (de)
NO2015020I2 (no) Ceritinib eller et farmasøytisk akseptabelt salt derav
GEP20084357B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
DK1406876T3 (da) 2-anilinopyrimidinderivater som inhibitorer af cyclinafhængige kinaser
GEP20053479B (en) Pyrrolo[2,3-d]Pyrimidine Compounds, Pharmaceutical Composition Containing the Same and Use
GEP20063784B (en) Optical Resolution of (1-Benzyl-4- Methylpiperidin-3-Yl) -Methylamine Enantiomers and Use Thereof for Preparation of Pyrrolo 2,3-Pyrimidine Derivatives as Protein Kinases Inhibitors
DE69410121D1 (en) Dihydro pyrazolopyrrole
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
CA2461622A1 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
AU2001234314A1 (en) Novel phenylheteroalkylamine derivatives
SE9901530D0 (sv) Novel compounds
BR122014024864B8 (pt) derivado de pirimidina, processo para preparar um derivado de pirimidina, composição farmacêutica, e, uso de um derivado de pirimidina